CME

This activity is supported by an educational grant from Bausch + Lomb.

Innovative Targeting of IOP, Emerging New Science in Glaucoma Management

Innovative Targeting of IOP, Emerging New Science in Glaucoma Management

This activity is supported by an educational grant from Bausch + Lomb.

Overview

Author(s)/Faculty: Robert J. Noecker, MD, MBA; Thomas W. Samuelson, MD
Source: Healio - Ophthalmology Education Lab
Type: VideoArticles/Items: 4
Release Date: 12/27/2017Expiration Date: 12/26/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education

Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people affected by the condition. With the aging population, it is expected that the prevalence of glaucoma will continue to increase, resulting in an estimated 80 million people with glaucoma by 2020. Recent advances in imaging have facilitated earlier glaucoma diagnosis and subsequent timely initiation of therapy, potentially reducing irreversible blindness and loss of quality of life. Therapies for glaucoma either increase outflow or decrease production of aqueous humor to reduce intraocular pressure (IOP), but IOP must be tightly controlled to provide optimal patient outcomes. In this activity, leading clinicians will evaluate clinical evidence for the safety and efficacy of established, new, and emerging classes of glaucoma medications, as well as discuss their mechanisms of action for the effective management of IOP.

CME Information

page 1 of 7